MCLA-128 Fights NRG1 Fusion-Positive Cancers.
Two patients with KRAS-wild-type pancreatic ductal carcinoma and NRG1 fusions received the bispecific antibody MCLA-128, which led to tumor shrinkage. One experienced a partial response and the other had stable disease. A third patient with non-small cell lung cancer and an NRG1 fusion also experienced a partial response in a clinical proof-of-concept study.